Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + morphine + tramadol + ketamine
- Development stage
- Phase 4
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
paracetamol + morphine + tramadol + ketamine is a multimodal analgesic combination regimen being evaluated for the management of acute pain during vaso-occlusive crises (VOC) in adult patients with sickle cell disease. This combination leverages multiple distinct mechanisms of action to optimize pain control while potentially reducing overall opioid consumption and associated adverse effects. Paracetamol (acetaminophen) acts as a weak inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes to provide antipyretic and analgesic effects. Morphine is a potent mu-opioid receptor agonist that provides strong central analgesia. Tramadol acts as both a weak mu-opioid receptor agonist and a serotonin-norepinephrine reuptake inhibitor (SNRI), enhancing inhibitory pain pathways. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that provides additional co-analgesia and helps prevent opioid-induced hyperalgesia. The combination is being studied in the PAMAVOC adaptive platform trial sponsored by Assistance Publique - Hôpitaux de Paris.
- Other names
- acetaminophen + morphine + tramadol + ketamineparacetamol + morphine + tramadol + ketamine
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on paracetamol + morphine + tramadol + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + morphine + tramadol + ketamine.